COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT05374954

Not reported

Not reported

2022-05-16

Not recruiting

RCT

Randomized

Parallel

Blind label

multi-center

Prevention

inclusion criteria: healthy subjects aged 18 years old and above. by asking for medical history and physical examination, the investigator judged that the health condition is well. has been vaccinated 2 or 3 doses of inactivated covid-19 vaccine manufactured by bibp more than 3 months. female subjects of childbearing age are not nursing or pregnant at the time of enrolment (negative urine pregnancy test) and have no family planning within the first 12 months after enrolment. effective contraceptive measures have been taken within 2 weeks before inclusion. during the whole follow-up period of the study, be able and willing to complete the whole prescribed study plan. with self-ability to understand the study procedures, the informed consent & voluntarily sign an informed consent form and be able to comply with the requirements of the clinical study protocol.

confirmed or suspected cases of sars-cov-2 infection. has a history of sars, mers, sars-cov-2 infection (self-report, on-site inquiry). received one dose or more than 3 doses of inactivated covid-19 vaccine manufactured by bibp received covid-19 vaccine manufactured bu other companies (include mrna, recombinant protein vaccines, vector vaccines, inactivated vaccines, etc.) axillary body temperature > 37.3 ℃ before vaccination previous severe allergic reactions to vaccination (such as acute allergic reactions, urticaria, dyspnea, angioneurotic edema or abdominal pain) or allergy to known ingredients of inactivated sars-cov-2 vaccine have occurred (self-report, on-site inquiry). history of hospital-diagnosed thrombocytopenia or other coagulation disorder known immunological impairment or low level with hospital diagnosis history of uncontrolled epilepsy, other progressive neurological disorders, or guillain-barre syndrome (self-report, on-site inquiry). known or suspected concomitant serious diseases include: respiratory disease, acute infection or active chronic disease, liver and kidney disease, severe diabetes, malignant tumor, infection or allergic skin disease, hiv infection. severe cardiovascular disease (cardiopulmonary failure, uncontrolled hypertension, etc.) diagnosed by the hospital, active chronic respiratory disease received live attenuated vaccine within 1 month before enrollment. received other vaccines within 14 days before enrollment. be participating in or plan to participate in other vaccine clinical trials during this study. contraindications related to vaccination as considered by other investigators.

28

China National Biotec Group Company Limited

18

100

China

Healthy volunteers

N/A

4200

Incidence of adverse reactions;The four-fold increase rate of neutralizing antibody against Omicron SARS-CoV-2;The Geometric Mean Titer (GMT) of neutralizing antibody against Omicron SARS-CoV-2

None

Phase 3

[{"arm_notes": "Active Comparator: A2\uff1aone dose, 18-59 years old, from 3 months to 6 months after 2 doses of vaccination", "treatment_id": 1923, "treatment_name": "Inactivated sars-cov-2 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Active Comparator: A4\uff1aone dose, 18-59 years old, from 6 months to 12 months after 2 doses of vaccination", "treatment_id": 1923, "treatment_name": "Inactivated sars-cov-2 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Active Comparator: B2\uff1aone dose, 18-59 years old, from 3 months to 6 months after 3 doses of vaccination", "treatment_id": 1923, "treatment_name": "Inactivated sars-cov-2 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Experimental: B1\uff1aone dose, 18-59 years old, from 3 months to 6 months after 3 doses of vaccination\nsubjects aged 18-59 years old will be blinded and receive one dose from 3 months to 6 months after 3 doses of inactivated COVID-19 vaccine", "treatment_id": 2485, "treatment_name": "Omicron covid-19 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Active Comparator: B4\uff1aone dose, 18-59 years old, from 6 months to 12 months after 3 doses of vaccination", "treatment_id": 1923, "treatment_name": "Inactivated sars-cov-2 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Active Comparator: C2\uff1atwo doses, 18-59 years old, from 3 months to 6 months after 2 doses of vaccination", "treatment_id": 1923, "treatment_name": "Inactivated sars-cov-2 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Active Comparator: C4\uff1atwo doses, 18-59 years old, from 6 months to 12 months after 2 doses of vaccination", "treatment_id": 1923, "treatment_name": "Inactivated sars-cov-2 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Active Comparator: C6\uff1atwo doses, 18-59 years old, more than 12 months after 2 doses of vaccination", "treatment_id": 1923, "treatment_name": "Inactivated sars-cov-2 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Active Comparator: D2\uff1atwo doses, 60 years old and above, from 3 months to 6 months after 2 doses of vaccination", "treatment_id": 1923, "treatment_name": "Inactivated sars-cov-2 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Active Comparator: D4\uff1atwo doses, 60 years old and above, from 6 months to 12 months after 2 doses of vaccination", "treatment_id": 1923, "treatment_name": "Inactivated sars-cov-2 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Active Comparator: E2\uff1atwo doses, 18-59 years old, from 3 months to 6 months after 3 doses of vaccination", "treatment_id": 1923, "treatment_name": "Inactivated sars-cov-2 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Active Comparator: E4\uff1atwo doses, 18-59 years old, from 6 months to 12 months after 3 doses of vaccination", "treatment_id": 1923, "treatment_name": "Inactivated sars-cov-2 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Active Comparator: E6\uff1atwo doses, 18-59 years old, more than 12 months after 3 doses of vaccination", "treatment_id": 1923, "treatment_name": "Inactivated sars-cov-2 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Active Comparator: F2\uff1atwo doses, 60 years old and above, from 3 months to 6 months after 3 doses of vaccination", "treatment_id": 1923, "treatment_name": "Inactivated sars-cov-2 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Active Comparator: F4\uff1atwo doses, 60 years old and above, from 6 months to 12 months after 3 doses of vaccination", "treatment_id": 1923, "treatment_name": "Inactivated sars-cov-2 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Experimental: A1\uff1aone dose, 18-59 years old, from 3 months to 6 months after 2 doses of vaccination", "treatment_id": 2485, "treatment_name": "Omicron covid-19 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "xperimental: A3\uff1aone dose, 18-59 years old, from 6 months to 12 months after 2 doses of vaccination", "treatment_id": 2485, "treatment_name": "Omicron covid-19 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Experimental: B1\uff1aone dose, 18-59 years old, from 3 months to 6 months after 3 doses of vaccination\nsubjects aged 18-59 years old will be blinded and receive one dose from 3 months to 6 months after 3 doses of inactivated COVID-19 vaccine", "treatment_id": 2485, "treatment_name": "Omicron covid-19 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Experimental: B3\uff1aone dose, 18-59 years old, from 6 months to 12 months after 3 doses of vaccination", "treatment_id": 2485, "treatment_name": "Omicron covid-19 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Experimental: C1\uff1atwo doses, 18-59 years old, from 3 months to 6 months after 2 doses of vaccination\n", "treatment_id": 2485, "treatment_name": "Omicron covid-19 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Experimental: C3\uff1atwo doses, 18-59 years old, from 6 months to 12 months after 2 doses of vaccination", "treatment_id": 2485, "treatment_name": "Omicron covid-19 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Experimental: C5\uff1atwo doses, 18-59 years old, more than 12 months after 2 doses of vaccination", "treatment_id": 2485, "treatment_name": "Omicron covid-19 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Experimental: D1\uff1atwo doses, 60 years old and above, from 3 months to 6 months after 2 doses of vaccination", "treatment_id": 2485, "treatment_name": "Omicron covid-19 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Experimental: D3\uff1atwo doses, 60 years old and above, from 6 months to 12 months after 2 doses of vaccination", "treatment_id": 2485, "treatment_name": "Omicron covid-19 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Experimental: E1\uff1atwo doses, 18-59 years old, from 3 months to 6 months after 3 doses of vaccination", "treatment_id": 2485, "treatment_name": "Omicron covid-19 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Experimental: E3\uff1atwo doses, 18-59 years old, from 6 months to 12 months after 3 doses of vaccination", "treatment_id": 2485, "treatment_name": "Omicron covid-19 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Experimental: E5\uff1atwo doses, 18-59 years old, more than 12 months after 3 doses of vaccination", "treatment_id": 2485, "treatment_name": "Omicron covid-19 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Experimental: F1\uff1atwo doses, 60 years old and above, from 3 months to 6 months after 3 doses of vaccination", "treatment_id": 2485, "treatment_name": "Omicron covid-19 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Experimental: F3\uff1atwo doses, 60 years old and above, from 6 months to 12 months after 3 doses of vaccination", "treatment_id": 2485, "treatment_name": "Omicron covid-19 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}]